Saturday 17 October 2026 Export TNON’s income statement to Excel — free account

Tenon Medical, Inc.

Tenon Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 126.8%, EPS grew 1.88% and free cash flow fell 21.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

2.70 0.21 −7.22%

Follow TNON

Alert me

Market cap: $7.8M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 4/9
Altman Z: −13.00
Beneish M: −1.81
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.50

Total sells 0.61

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	3	—	—	—	—	—	—	—	—	1	3	—
Sell	—	—	—	—	—	—	—	—	—	2	3	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 7.82

Revenue 5.31

Net Income (13.70)

Free Cash Flow (12.82)

Net Debt (1.68)

Current Ratio 0.58

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.71)

P/S ratio 0.17

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 64.29%

Next Y EPS Growth 69.22%

Next Y revenue growth 46.86%

Next 5Y EPS Growth 43.91%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.18%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2	7	4	2
Receivables	1	1	2	2
Inventory	1	1	1	1
Other	—	—	—	—
	4	8	7	5

	2023	2024	2025	Q'26
Payables	0	0	1	1
ST’ Debt	—	—	—	—
Other	0	0	1	1
	3	2	3	8

Compound Annual Growth %

	10y	5y	3y
Sales	—	145.98%	78.71%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(6.93%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	1	1	1	4
’24	1	1	1	1	3
’23	0	1	1	1	3
’22	0	0	0	0	1
’21	0	0	0	0	0
’20	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(2)	(2)	(4)	(2)	(11)
’24	(2)	(2)	(2)	(3)	(10)
’23	(4)	(3)	(3)	(2)	(12)
’22	(2)	(3)	(3)	(3)	(12)
’21	0	(1)	(1)	(2)	(4)
’20	—	—	—	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(2)	(2)	(4)	(2)	(12)
’24	(2)	(2)	(2)	(3)	(10)
’23	(4)	(3)	(3)	(2)	(13)
’22	(3)	(3)	(3)	(4)	(13)
’21	0	(1)	(1)	(2)	(4)
’20	—	—	—	0	0

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(10.84)	(12.35)	—	—	—
’25	(35.31)	(12.59)	(13.99)	(7.69)	(59.44)
’24	(349.65)	(285.31)	(126.92)	368.61	(393.71)
’23	(1.20k)	(923.08)	(408.39)	(190.21)	(2.40k)
’22	(6.66k)	(1.82k)	(783.22)	(1.96k)	(6.60k)
’21	(677.39)	(5.64k)	(7.19k)	(8.42k)	(21.85k)
’20	—	—	—	—	(2.38k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	3,192.00	215.60	58.45	29.75	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	167,692.00	7,672.00	552.58	204.75
People
People	Employees	—	—	—	—	—	10	22	21	27	26
	Revenue/emp, $m	—	—	—	0.00	0.00	0.02	0.03	0.14	0.12	0.15
Income, $m
Income, $m	Revenue	—	—	—	0	0	0	1	3	3	4
	Gross margin, %	—	—	—	66.04	58.45	65.63	(92.76)	42.38	52.21	59.79
	EBT	—	—	—	(1)	(1)	(7)	(19)	(16)	(14)	(13)
	EBT margin, %	—	—	—	(1,092.91)	(1,610.50)	(4,425.63)	(2,737.63)	(532.14)	(417.24)	(318.36)
	Net income	—	—	—	(1)	(1)	(7)	(19)	(16)	(14)	(13)
	Depreciation	—	—	—	—	—	0	0	0	1	1
Per share, $
Per share, $	Revenue	—	—	—	0.05	146.00	533.33	238.28	450.46	94.44	18.67
	Earnings	—	—	—	(0.45)	(2,377.17)	(21,846.15)	(6,601.40)	(2,402.80)	(393.71)	(59.44)
	Cash flow	—	—	—	(0.21)	(558.00)	(14,306.67)	(4,146.55)	(1,874.31)	(284.67)	(50.88)
	Capex	—	—	—	0.00	0.00	(340.00)	(292.07)	(55.54)	(5.36)	(4.84)
	Free cash flow	—	—	—	(0.21)	(558.00)	(14,646.67)	(4,438.62)	(1,929.85)	(290.03)	(55.72)
	Book value	—	—	—	(2.32)	(7,123.00)	(23,043.33)	2,155.86	119.69	172.07	23.86
	Shares, m	—	—	—	1	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	116.67	116.67	116.67	18.68	0.96	0.70	1.78
	P/B	—	—	—	0.00	0.00	0.00	2.07	3.63	1.03	3.58
	EV/Sales	—	—	—	96.56	96.56	96.56	6.77	0.25	(1.20)	0.92
	EV/FCF	—	—	—	(3.06)	(3.06)	(3.06)	(0.36)	(0.06)	0.39	(0.31)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	0	0	(4)	(12)	(12)	(10)	(11)
	Capex	—	—	—	—	—	0	(1)	0	0	(1)
	Free cash flow	—	—	—	0	0	(4)	(13)	(13)	(10)	(12)
Balance, $m
Balance, $m	Working capital	—	—	—	(1)	(1)	(8)	7	1	6	4
	Total debt	—	—	—	1	0	1	1	—	—	—
	Net debt	—	—	—	1	0	(7)	(9)	(2)	(7)	(4)
	Shareholders’ equity	—	—	—	(3)	(2)	(7)	6	1	6	5
Returns, %
Returns, %	ROA	—	—	—	0.00	(177.49)	(145.88)	(185.82)	(178.74)	(168.93)	(121.89)
	ROIC	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	(622.66)
	ROE	—	—	—	0.00	16.06	58.83	264.57	(443.27)	(912.45)	(600.05)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%	Compare
CTSO Cytosorbents Corporation	$9.7M	— (loss-making)	— (loss-making)	+0.17% (above 0%: growing)	n/m	+64.90% (above 0%: growing)	73.18%	(27.39%)	Compare
NMTC NeuroOne Medical Technologies Corporation	$9.5M	— (loss-making)	— (loss-making)	+16.33% (above 0%: growing)	n/m	+26.91% (above 0%: growing)	59.94%	(122.87%)	Compare
BMRA Biomerica, Inc.	$8.6M	— (loss-making)	11.4×	+16.96% (above 0%: growing)	n/m	−35.05% (below 0%: shrinking)	(7.88%)	(174.77%)	Compare
AEMD Aethlon Medical, Inc.	$8.5M	— (loss-making)	— (loss-making)	+335.00% (above 0%: growing)	n/m	−11.13% (below 0%: shrinking)	0.00%	0.00%	Compare
TNON Tenon Medical, Inc.	$7.8M	— (loss-making)	— (loss-making)	+126.77% (above 0%: growing)	n/m	−21.78% (below 0%: shrinking)	63.64%	(262.24%)
WOK WORK Medical Technology Group LTD	$6.0M	—	—	—	—	−948.94% (below 0%: shrinking)	—	—	Compare
AMIX Autonomix Medical, Inc.	$5.7M	— (loss-making)	—	—	n/m	−36.10% (below 0%: shrinking)	—	0.00%	Compare
NVNO enVVeno Medical Corporation	$5.5M	— (loss-making)	— (loss-making)	+0.32% (above 0%: growing)	n/m	+4.60% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$8.5M	—	—	+13.37%	—	−3.26%	29.97%	0.00%

All 149 Medical Devices stocks →

Tenon Medical, Inc. (TNON) key facts

Strength: Tenon Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, up 20.4% from fiscal 2024.
Tenon Medical, Inc. (TNON) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TNON traded at $2.70, a market capitalization of $7.8 million.
Return on equity was −600.1% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −13.00 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.